CUMBERLAND, R.I.– Neurotech Pharmaceuticals, Inc., a private biotechnology company developing therapies for chronic eye diseases, today announced the appointment of Peter J. McDonnell, M.D., to its Board of Directors.
Dr. McDonnell has been the William Holland Wilmer Professor of Ophthalmology and Director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine since 2003. A board-certified ophthalmologist specializing in corneal disease and surgery, he is recognized globally for his contributions to corneal transplantation, laser refractive surgery, and dry eye treatment. He has published more than 250 scientific articles, holds ten patents, and serves on the editorial boards of numerous ophthalmology journals.
Dr. McDonnell is Chief Medical Editor of Ophthalmology Times, Immediate Past President of the National Alliance for Eye and Vision Research, Vice President of the Pan-American Ophthalmological Association, and has previously served on the boards of Allergan and Aerie Pharmaceuticals.
“We are thrilled to welcome Dr. McDonnell to Neurotech’s Board of Directors,” said Jim Mazzo, Executive Chairman of Neurotech. “His exceptional leadership in ophthalmology and dedication to advancing vision science make him an ideal addition to our team. Peter’s guidance will be pivotal as we continue to advance innovative solutions for chronic eye diseases.”
“I am honored to join Neurotech’s Board at such an exciting time in the company’s evolution,” said Peter J. McDonnell, M.D. “Neurotech’s commitment to scientific excellence closely aligns with my lifelong dedication to improving patient outcomes. I look forward to working with the team as it advances meaningful treatments in ophthalmic care.”
